[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606325":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients undergoing radiotherapy",null,"The individuals studied will all be patients administered with radiopharmaceuticals for diagnostic and therapy purposes (aged between 18 and 90).",[13],"Other: RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.","Acquisition of data during the infusion of PET radiotracers and the administration of α and β emitting radiopharmaceuticals for therapy.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Mauro Iori, MD","CONTACT","0522\u002F296655","mauro.iori@ausl.re.it",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Federica Fioroni, MD","0522\u002F296653","federica.fioroni@ausl.re.it",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Azienda USL IRCCS di Reggio Emilia","RECRUITING","Reggio Emilia","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],10.63125,44.69825,{"lat":41,"lon":40},[44],{"name":22,"role":45,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100606325","new-ai-based-technologies-in-nuclear-medicine-100606325",false,"NCT07174089","New AI-based Technologies in Nuclear Medicine","New AI-based Technologies for Even Safer and More Precise Nuclear Medicine","AI-basedMedNuc","Inclusion Criteria:\n\n* patients undergoing PET\u002FCT scans or therapeutic treatments with radiopharmaceuticals labelled with alpha or beta emitting nuclides\n\nExclusion Criteria:\n\n* patients whose clinical or psychological conditions do not allow for their involvement","ALL","18 Years","90 Years",{"count":60,"type":61},1500,"ESTIMATED","OBSERVATIONAL","The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET\u002FCT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.",[65],"Patients Undergoing PET\u002FCT Investigation or Nuclear Medicine Therapy",[67,68,69,70,71],"extravasation","SUV","radioligand therapy","radiopharmaceutical","dosimetry","2026-05-28",{"date":74,"type":75},"2026-05-29","ACTUAL",{"date":77,"type":75},"2021-07-30",{"date":79,"type":61},"2026-12-31",{"name":5,"class":6},1]